Proteomics of Peripheral Leukocytes in Patients with Elevated Serum Levels of PSA
Abstract
During this second year of research, we have modified patient recruitment protocols for a greater sample acquisition rate, and initiated studies in mouse models of prostate cancer. This will allow us to reduce the influence of genetic heterogeneity observed in human populations, and increase our confidence that observed differences in protein levels are the result of a malignant process. From collected patient samples, we now are able to isolate CD4+ T-lymphocytes and monocytes at high yield and high purity, and analyze them by mass spectrometry. We have observed a total of 1190 proteins from monocytes by two or more peptides from these samples. At this early stage, there are numerous proteins which could become candidates for discriminating between prostate cancer and benign prostate diseases in the setting of an elevated PSA. However, the main task in the coming year will be the analysis of a much larger number of samples, in order to achieve statistical significance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2011
- Accession Number
- ADA554552
Entities
People
- Martin Steffen
Organizations
- Boston University